Companies › Heartseed
2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HS-005 Allogeneic iPSC-derived cardiomyocyte spheroids transplantation | – | Phase 1 | Heart Failure | Jan 2028 |
| HS-001 CS Human allogeneic iPS cell-derived cardiomyocyte spheroids | – | Phase 1 | Heart Failure | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04945018 | HS-001 CS | Phase 1 | Heart Failure | Cardiovascular | Jul 2025 |
| NCT07347197 | HS-005 | Phase 1 | Heart Failure | Cardiovascular | Jan 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.